Merck KGaA has acquired worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by Peptimmune Inc.
PI-2301 has completed Phase 1b in multiple sclerosis and is ready to initiate Phase 2 clinical trials.
“Over the years we have continuously worked on developing innovative treatment options that meet the individual needs of people living with multiple sclerosis,” said Susan Herbert, Head of Global Portfolio Development at the Merck Serono division.
“We are pleased to strengthen our development pipeline with the PI-2301 compound, which could play a valuable role in the treatment of this debilitating disease.”
The acquisition of PI-2301 covers its worldwide exclusive development and commercialization rights.
PI-2301 is a second-generation peptide copolymer that is thought to enhance the regulatory response of the immune system.
Merck will investigate the application of this product in autoimmune diseases such as multiple sclerosis.